Checchi Capital Advisers LLC raised its position in shares of CVS Health Co. (NYSE:CVS – Get Rating) by 20.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,147 shares of the pharmacy operator’s stock after purchasing an additional 2,229 shares during the period. Checchi Capital Advisers LLC’s holdings in CVS Health were worth $1,331,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in CVS. Macroview Investment Management LLC increased its holdings in shares of CVS Health by 128.3% during the 1st quarter. Macroview Investment Management LLC now owns 242 shares of the pharmacy operator’s stock valued at $25,000 after acquiring an additional 136 shares during the last quarter. West Bancorporation Inc. acquired a new position in shares of CVS Health during the 4th quarter valued at about $25,000. Claremont Financial Group Inc. acquired a new position in shares of CVS Health during the 4th quarter valued at about $26,000. Stuart Chaussee & Associates Inc. increased its holdings in shares of CVS Health by 123.0% during the 1st quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator’s stock valued at $31,000 after acquiring an additional 171 shares during the last quarter. Finally, Capital Advisors Ltd. LLC increased its holdings in shares of CVS Health by 125.7% during the 4th quarter. Capital Advisors Ltd. LLC now owns 316 shares of the pharmacy operator’s stock valued at $33,000 after acquiring an additional 176 shares during the last quarter. 78.00% of the stock is owned by hedge funds and other institutional investors.
CVS Health Price Performance
CVS Health stock opened at $102.26 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.91 and a quick ratio of 0.62. The company has a market capitalization of $134.25 billion, a PE ratio of 16.63, a price-to-earnings-growth ratio of 1.55 and a beta of 0.75. CVS Health Co. has a one year low of $80.15 and a one year high of $111.25. The business has a 50 day simple moving average of $94.36 and a 200 day simple moving average of $99.93.
CVS Health Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 1st. Shareholders of record on Friday, July 22nd were given a $0.55 dividend. The ex-dividend date of this dividend was Thursday, July 21st. This represents a $2.20 annualized dividend and a yield of 2.15%. CVS Health’s payout ratio is 35.77%.
Insider Buying and Selling at CVS Health
In other CVS Health news, EVP Alan Lotvin sold 22,541 shares of CVS Health stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $104.00, for a total value of $2,344,264.00. Following the completion of the transaction, the executive vice president now owns 109,183 shares in the company, valued at approximately $11,355,032. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Alan Lotvin sold 22,541 shares of CVS Health stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $104.00, for a total value of $2,344,264.00. Following the completion of the sale, the executive vice president now directly owns 109,183 shares of the company’s stock, valued at approximately $11,355,032. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Thomas M. Moriarty sold 138,654 shares of CVS Health stock in a transaction on Tuesday, June 28th. The shares were sold at an average price of $95.00, for a total value of $13,172,130.00. Following the completion of the sale, the executive vice president now directly owns 626,273 shares of the company’s stock, valued at $59,495,935. The disclosure for this sale can be found here. Corporate insiders own 0.69% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the company. Loop Capital began coverage on CVS Health in a report on Thursday, June 16th. They set a “buy” rating and a $120.00 price objective on the stock. Deutsche Bank Aktiengesellschaft raised their target price on CVS Health from $113.00 to $120.00 in a report on Thursday. UBS Group raised their target price on CVS Health from $118.00 to $127.00 and gave the company a “buy” rating in a report on Thursday. Finally, Sanford C. Bernstein lowered CVS Health from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $122.00 to $112.00 in a report on Thursday, May 26th. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $116.90.
CVS Health Company Profile
CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.
Read More
- Get a free copy of the StockNews.com research report on CVS Health (CVS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.